Decreased serum levels of thioredoxin in patients with coronary artery disease plus hyperhomocysteinemia is strongly associated with the disease severity

Atherosclerosis

Volumn 212, Issue 1, 2010, Pages 351-355

  Wu, Yunfei ^a   Yang, Lijuan ^b   Zhong, Liangwei ^a  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Coronary artery disease; Homocysteine; Human serum; Thioredoxin; Thioredoxin reductase

Indexed keywords

ATORVASTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; THIOREDOXIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHINA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERHOMOCYSTEINEMIA; LIPIDS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THIOREDOXIN-DISULFIDE REDUCTASE; THIOREDOXINS;

EID: 77956226935     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.06.002     Document Type: Article

References (30)

1. Nygard O., Nordrehaug J.E., Refsum H., et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997, 337:230-236.
2. Zou C.G., Banerjee R. Homocysteine and redox signaling. Antioxid Redox Signal 2005, 7:547-559.
3. Tyagi N., Sedoris K.C., Steed M., et al. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol 2005, 289:H2649-H2656.
4. Dai J., Wang X., Feng J., et al. Regulatory role of thioredoxin in homocysteine-induced monocyte chemoattractant protein-1 secretion in monocytes/macrophages. FEBS Lett 2008, 582:3893-3898.
5. Cha M.K., Kim I.H. Thioredoxin-linked peroxidase from human red blood cell: evidence for the existence of thioredoxin and thioredoxin reductase in human red blood cell. Biochem Biophys Res Commun 1995, 217:900-907.
6. Kim H.Y., Kim J.R. Thioredoxin as a reducing agent for mammalian methionine sulfoxide reductases B lacking resolving cysteine. Biochem Biophys Res Commun 2008, 371:490-494.
7. Cheng Z., Arscott L.D., Ballou D.P., et al. The relationship of the redox potentials of thioredoxin and thioredoxin reductase from Drosophila melanogaster to the enzymatic mechanism: reduced thioredoxin is the reductant of glutathione in Drosophila. Biochemistry 2007, 46:7875-7885.
8. Holmgren A. Thioredoxin. Annu Biochem Rev 1985, 54:237-271.
9. Song J.J., Lee Y.J. Differential role of glutaredoxin and thioredoxin in metabolic oxidative stress-induced activation of apoptosis signal-regulating kinase 1. Biochem J 2003, 373:845-853.
10. Holmgren A., Johansson C., Berndt C., et al. Thiol redox control via thioredoxin and glutaredoxin systems. Biochem Soc Trans 2005, 33:1375-1377.
11. Zhong L., Holmgren A. Mammalian thioredoxin reductases as hydroperoxide reductases. Methods Enzymol 2002, 347:236-243.
12. Bjornstedt M., Hamberg M., Kumar S., et al. Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. J Biol Chem 1995, 270:11761-11764.
13. May J.M., Mendiratta S., Hill K.E., et al. Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase. J Biol Chem 1997, 272:22607-22610.
14. Benhar M., Forrester M.T., Stamler J.S. Protein denitrosylation: enzymatic mechanisms and cellular functions. Nat Rev Mol Cell Biol 2009, 10:721-732.
15. Arner E.S., Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000, 267:6102-6109.
16. Hagg D., Englund M.C., Jernas M., et al. Oxidized LDL induces a coordinated up-regulation of the glutathione and thioredoxin systems in human macrophages. Atherosclerosis 2006, 185:282-289.
17. Sahaf B., Rosen A. Secretion of 10-kDa and 12-kDa thioredoxin species from blood monocytes and transformed leukocytes. Antioxid Redox Signal 2000, 2:717-726.
18. Miyamoto S., Kawano H., Hokamaki J., et al. Increased plasma levels of thioredoxin in patients with glucose intolerance. Intern Med 2005, 44:1127-1132.
19. Soejima H., Suefuji H., Miyamoto S., et al. Increased plasma thioredoxin in patients with acute myocardial infarction. Clin Cardiol 2003, 26:583-587.
20. Nishihira K., Yamashita A., Imamura T., et al. Thioredoxin in coronary culprit lesions: possible relationship to oxidative stress and intraplaque hemorrhage. Atherosclerosis 2008, 201:360-367.
21. Malinow M.R. Plasma homocyst(e)ine and arterial occlusive diseases: a mini-review. Clin Chem 1995, 41:173-176.
22. Gensini G.G. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983, 51:606.
23. Das K.C., Das C.K., Thioredoxin a singlet oxygen quencher and hydroxyl radical scavenger: redox independent functions. Biochem Biophys Res Commun 2000, 277:443-447.
24. Hashimoto S., Matsumoto K., Gon Y., et al. Thioredoxin negatively regulates p38 MAP kinase activation and IL-6 production by tumor necrosis factor-alpha. Biochem Biophys Res Commun 1999, 258:443-447.
25. Weichsel A., Gasdaska J.R., Powis G., et al. Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer. Structure 1996, 4:735-751.
26. Lubos E, Loscalzo J., Handy D.E. Homocysteine and glutathione peroxidase-1. Antioxid Redox Signal 2007, 9:1923-1940.
27. Moon S., Fernando M.R., Lou M.F. Induction of thioltransferase and thioredoxin/thioredoxin reductase systems in cultured porcine lenses under oxidative stress. Invest Ophthalmol Vis Sci 2005, 46:3783-3789.
28. Lim H.W., Hong S., Jin W., et al. Up-regulation of defense enzymes is responsible for low reactive oxygen species in malignant prostate cancer cells. Exp Mol Med 2005, 37:497-506.
29. Lu J., Zhong L., Lonn M.E., et al. Penultimate selenocysteine residue replaced by cysteine in thioredoxin reductase from selenium-deficient rat liver. FASEB J 2009, 23:2394-2402.
30. Baber U., Toto R.D., de Lemos J.A. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. Am Heart J 2007, 153:471-477.